Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
510
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience

Luca LaurentiCatholic University of the Sacred Heart, Rome, Italy; Correspondence[email protected]
,
Francesco AutoreCatholic University of the Sacred Heart, Rome, Italy;
,
Idanna InnocentiCatholic University of the Sacred Heart, Rome, Italy;
,
Giovanni D’ArenaIRCCS Centro Di Riferimento Oncologico Della Basilicata, Rionero in Vulture, Italy;
,
Marta CosciaDivision of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy;
,
Patrizia MondelloDepartment of Human Pathology, University of Messina, Messina, Italy;
,
Patrizia ChiusoloCatholic University of the Sacred Heart, Rome, Italy;
,
Silvia BellesiCatholic University of the Sacred Heart, Rome, Italy;
,
Dimitar G. EfremovInternational Center for Genetic Engineering & Biotechnology, Monterotondo Scalo, Italy;
,
Simona SicaCatholic University of the Sacred Heart, Rome, Italy;
&
Francesca Romana MauroDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
 show all
Pages 2429-2431 | Received 07 Aug 2015, Accepted 23 Dec 2015, Published online: 27 Jan 2016

References

  • Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786–2792.
  • Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116:4771–4776.
  • Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141:615–621.
  • Shvidel L, Tadmor T, Braester A, et al. Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases. Ann Hematol. 2013;92:661–667.
  • Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820–1826.
  • Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89:1055–1062.
  • Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96:752–761.
  • Borthakur G, O’Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors. Br J Haematol. 2007;136:800–805.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol. 2010;66:413–423.
  • Goldschmidt N, Gural A, Ben-Yehuda D, et al. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2013;72:709–713.
  • Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010;10:21–27.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–3216.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.